NCT00799396View on ClinicalTrials.gov

Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)

PHASE4CompletedINTERVENTIONAL
Enrollment

682

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Platelet Aggregation InhibitorsCoronary Heart Disease
Interventions
DRUG

Clopidogrel

300 mg on first day, then 75 mg per day for the next 6 days

DRUG

Aspirin

Single dose of 324 mg on the last day of clopidogrel treatment

Trial Locations (1)

17601

Amish Research Clinic, Lancaster

All Listed Sponsors
collaborator

National Institute of General Medical Sciences (NIGMS)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Maryland, Baltimore

OTHER

NCT00799396 - Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study) | Biotech Hunter | Biotech Hunter